Navigation Links
New markers could improve treatment and survival in acute lymphoblastic leukaemia
Date:12/21/2012

This release is available in Spanish.

Acute lymphoblastic leukaemia, the most common paediatric cancer, has been the subject of study in the PhD thesis of ElixabetLpez.In the work entitled New genetic markers for treatment personalization in paediatric Acute Lymphoblastic Leukaemia, the UPV/EHU biologist has presented new genetic markers that could improve the classification of risk groups and predict treatment toxicity in the patient.That way it would be possible to achieve better personalisation of the treatment.

Over the last few decades survival has increased from 10% to 80%.This improvement has been achieved by using combined therapies and separating the patients into risk groups.For example, stronger treatmentis used in the groups in which a worse response is expected.That way the survival probability in the groups with a poor prognosis is increased, while chemotherapy toxicity in patients with a better prognosis is reduced.

However, the classification of the risk groups, which today is carried out by means of clinical markers, like the number of lymphocytes or age of the patient, and some genetic markers, is not totally exact.For example, some of the patients initially considered as lower risk do not respond well to the treatment and in the middle of their treatment their therapy is changed to that of greater risk.In these cases, "survival could be improved as the condition would be treated more intensively right from the start," points out Lpez.

On the other hand, children with acute lymphoblastic leukaemia receive very strong doses of chemotherapy, and toxicity problems, which can be very serious, often occur.What is more, "as they are children and the toxicity can leave them with sequelae for the rest of their lives, it is quite important to try and prevent it," says Lpez.Currently, there is no toxicity marker that is used in a standard way.

Quest for new markers

To find new risk markers, the whole genome of tumour cells was combed in the search for deletions and duplications.And the ones that were recurrent and which were exclusive to a risk group were selected, and so were the ones that were found in the patients who were moved from one group to another."We have found a low risk marker which only appears in low risk patients and another that only appears in high risk ones, which could complement the ones that are already being used.And another 5 markers that appear in patients that were changed from low risk to high risk, and in those of high risk.This means that those patients were in fact high risk ones and that they should have been included in that group," explains the author.

On the other hand, the toxicity markers were sought in normal cells to detect variations that are of the individual and not of the tumour.This study has focussed on methotrexate, one of the most important drugs that can cause toxicity.And several possible markers have been found, like some variants of the methotrexate transporter gene and other variants related to microRNAs (short ribonucleic acid molecules which do not give rise to proteins but which carry out a significant regulatory function) that regulate the genes.

Lpez's next aim is to study how the genetic variations found affect gene expression and see exactly why these variations are regulating toxicity or response to treatment. Furthermore, to validate the markers, they are endeavouring to set up some clinical trials."We have found these associations in our population, but a clinical trial would be needed to see whether they really are good markers and whether, in actual fact, survival and toxicity are improved when these markers are used," saysLpez.


'/>"/>

Contact: Aitziber Lasa
a.lasa@elhuyar.com
34-943-363-040
Elhuyar Fundazioa
Source:Eurekalert  

Related medicine news :

1. Kentucky team inhibits Alzheimers biomarkers in animal model by targeting astrocytes
2. Metabolic biomarkers for preventive molecular medicine
3. Tracking down smallest biomarkers
4. Biomarkers of behavior, therapeutic targets for adult B-acute lymphoblastic leukemia identified
5. Genetic markers for testosterone and estrogen level regulation identified
6. BUSM researchers identify genetic markers for testosterone, estrogen level regulation
7. US Army: Pre-injury cartilage biomarkers associated with subsequent ACL injuries
8. Using biomarkers to identify and treat schizophrenia
9. Novel biomarkers reveal evidence of radiation exposure
10. Mayo Clinic researchers discover biomarkers for prostate cancer detection, recurrence
11. Biomarkers can reveal IBS
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New markers could improve treatment and survival in acute lymphoblastic leukaemia
(Date:7/21/2017)... ... July 21, 2017 , ... Hospital M&A activity slowed in the ... number of hospital acquisitions rose to 23 in the second quarter, up 15% from ... from the 20 announced deals in the year-ago second quarter. Only four of the ...
(Date:7/21/2017)... ... ... The House of Yahweh in Abilene, Texas, has written a new post this week that ... to be more open about positive changes. Yisrayl says the use of force is not ... positive way to solve all; yes, all issues, and he is ready to share this ...
(Date:7/21/2017)... ... July 21, 2017 , ... “Kids aren't born knowing ... tie their shoes,” says Suzanne Tucker, Founder of St. Louis-based positive education company Generation ... launches on Kickstarter on Monday, July 21st. , The kit uses colorful, engaging ...
(Date:7/21/2017)... TORONTO, ONTARIO, CANADA (PRWEB) , ... July 21, ... ... with over 80% follow-up at 10 years, researchers from the Multicenter Orthopaedics Outcome ... knee-related quality of life a decade after surgery, though activity levels decline over ...
(Date:7/20/2017)... ... July 20, 2017 , ... TransPixel Volume 2 is ... clips in the FCPX timeline. This effect isolates horizontal and vertical lines of pixels ... contains either a rotating or flipping animation and can be changed using a drop-down ...
Breaking Medicine News(10 mins):
(Date:7/5/2017)... , July 5, 2017 Oramed ... www.oramed.com ), a clinical-stage pharmaceutical company focused on ... it has received approval from the Israel Securities Authority to ... (TASE). Oramed common stock will commence trading on the TASE ... the current market capitalization of the Company, it is expected ...
(Date:7/1/2017)... WARSAW, Ind. , June 30, 2017 Zimmer ... second quarter sales and earnings conference call will be broadcast ... 8 a.m. Eastern Time.  A news release detailing the quarterly ... the morning of the conference call. The live ... website at http://investor.zimmerbiomet.com . It will be archived for ...
(Date:6/30/2017)... , June 29, 2017  Axium Pharmaceuticals Inc. is a pharmaceutical ... novel formulations and alternative dosage forms of existing biologically active ... ... on our waterless self-nano emulsifying formula, which is designed to ... We believe the spray will provide fast onset of action ...
Breaking Medicine Technology: